MOREPENLAB

Morepen Laboratories Share Price

₹73.85 -2.08 (-2.74%)

21 Nov, 2024 14:11

SIP TrendupStart SIP in MOREPENLAB

Start SIP

Performance

  • Low
  • ₹74
  • High
  • ₹76
  • 52 Week Low
  • ₹39
  • 52 Week High
  • ₹101
  • Open Price₹76
  • Previous Close₹76
  • Volume3,637,973

Investment Returns

  • Over 1 Month -13.59%
  • Over 3 Month + 8.61%
  • Over 6 Month + 54.34%
  • Over 1 Year + 86.46%
SIP Lightning

Smart Investing Starts Here Start SIP with Morepen Laboratories for Steady Growth!

Invest Now

Morepen Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 30.8
  • PEG Ratio
  • 0.2
  • Market Cap Cr
  • 4,047
  • P/B Ratio
  • 4.8
  • Average True Range
  • 4.05
  • EPS
  • 2.4
  • Dividend Yield
  • 0
  • MACD Signal
  • -1.21
  • RSI
  • 41.24
  • MFI
  • 39.92

Morepen Laboratories Financials

Morepen Laboratories Technicals

EMA & SMA

Current Price
₹73.85
-2.08 (-2.74%)
pointer
  • stock-down_img
  • Bullish Moving Average 3
  • stock-up_img
  • Bearish Moving Average 13
  • 20 Day
  • ₹79.72
  • 50 Day
  • ₹80.03
  • 100 Day
  • ₹74.72
  • 200 Day
  • ₹65.24

Resistance and Support

75.77 Pivot Speed
  • R3 79.49
  • R2 78.20
  • R1 77.06
  • S1 74.63
  • S2 73.34
  • S3 72.20

What's your outlook on Morepen Laboratories?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Morepen Laboratories Ltd. is a leading pharmaceutical company in India, specializing in Active Pharmaceutical Ingredients (APIs), formulations, diagnostics, and over-the-counter (OTC) products. It exports to over 75 countries, with a strong focus on APIs like Loratadine.

Morepen Laboratories has an operating revenue of Rs. 1,760.57 Cr. on a trailing 12-month basis. An annual revenue growth of 20% is outstanding, Pre-tax margin of 8% is okay, ROE of 11% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and around 23% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 24% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 80 which is a GOOD score indicating consistency in earnings, a RS Rating of 81 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 39 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Morepen Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-11 Quarterly Results
2024-08-12 Quarterly Results
2024-05-21 Audited Results
2024-01-31 Quarterly Results
2023-11-02 Quarterly Results

Morepen Laboratories F&O

Morepen Laboratories Shareholding Pattern

35.65%
0%
0.94%
2.08%
0.68%
48.16%
12.49%

About Morepen Laboratories

  • NSE Symbol
  • MOREPENLAB
  • BSE Symbol
  • 500288
  • Chairman & Managing Director
  • Mr. Sushil Suri
  • ISIN
  • INE083A01026

Similar Stocks to Morepen Laboratories

Morepen Laboratories FAQs

Morepen Laboratories share price is ₹73 As on 21 November, 2024 | 13:57

The Market Cap of Morepen Laboratories is ₹4046.6 Cr As on 21 November, 2024 | 13:57

The P/E ratio of Morepen Laboratories is 30.8 As on 21 November, 2024 | 13:57

The PB ratio of Morepen Laboratories is 4.8 As on 21 November, 2024 | 13:57

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23